Novo Nordisk Narrows 2024 Guidance Range, Q3 in Line with Expectations

Reuters11-06

COPENHAGEN, Nov 6 (Reuters) - Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.

Novo Nordisk shares gained 4.4% in overnight trading.

The maker of popular weight-loss drug Wegovy said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth.

Operating profit growth this year is now seen at between 21% and 27% in local currencies, compared to its previous forecast of 20% to 28%.

Novo Nordisk has raised its 2024 sales growth outlook twice since the beginning of the year. In August, however, the company cut its expectations for operating profit growth.

"The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before," CEO Lars Fruergaard Jorgensen said in a statement.

Novo said operating profit between July and September rose 26% to 33.8 billion Danish crowns ($4.86 billion) compared with 33.6 billion forecast by analysts in a poll gathered by the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

5

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481635649?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 14:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481635649","market":"us","top_or_hot":-1,"title":"Novo Nordisk Narrows 2024 Guidance Range, Q3 in Line with Expectations","media":"Reuters","content":"<html><head></head><body><p>COPENHAGEN, Nov 6 (Reuters) - Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.</p><p>Novo Nordisk shares gained 4.4% in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/328634a52776508c9db10758a5a7e749\" tg-width=\"538\" tg-height=\"181\"/></p><p>The maker of popular weight-loss drug Wegovy said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth.</p><p>Operating profit growth this year is now seen at between 21% and 27% in local currencies, compared to its previous forecast of 20% to 28%.</p><p>Novo Nordisk has raised its 2024 sales growth outlook twice since the beginning of the year. In August, however, the company cut its expectations for operating profit growth.</p><p>&#34;The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,&#34; CEO Lars Fruergaard Jorgensen said in a statement.</p><p>Novo said operating profit between July and September rose 26% to 33.8 billion Danish crowns ($4.86 billion) compared with 33.6 billion forecast by analysts in a poll gathered by the company.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Narrows 2024 Guidance Range, Q3 in Line with Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Narrows 2024 Guidance Range, Q3 in Line with Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 14:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL8N3MD17Q:3><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>COPENHAGEN, Nov 6 (Reuters) - Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL8N3MD17Q:3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"0QIU.UK","symbol_name":"NOVO NORDISK B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL8N3MD17Q:3","article_id":"2481635649","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481635649","pubTimestamp":1730876089,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 2-Novo Nordisk narrows 2024 guidance range, Q3 in line with expectationsAdds FY outlook in paragraph 2-4. COPENHAGEN, Nov 6  - Weight-loss and diabetes drugmaker Novo Nordisk NOVOb.CO on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.The maker of popular weight-loss drug Wegovy said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth.Operating profit growth this year is now seen at between 21% and 27% in local currencies, compared to its previous forecast of 20% to 28%.\"The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,\" CEO Lars Fruergaard Jorgensen said in a statement.Novo said operating profit between July and September rose 26% to 33.8 billion Danish crowns  compared with 33.6 billion forecast by anal","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"0QIU.UK":"NOVO NORDISK B","NVO":"诺和诺德"},"translate_title":"诺和诺德缩小2024年指导范围，第三季度符合预期","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"0QIU.UK":1.1,"NVO":1.1},"content_text":"COPENHAGEN, Nov 6 (Reuters) - Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.Novo Nordisk shares gained 4.4% in overnight trading.The maker of popular weight-loss drug Wegovy said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth.Operating profit growth this year is now seen at between 21% and 27% in local currencies, compared to its previous forecast of 20% to 28%.Novo Nordisk has raised its 2024 sales growth outlook twice since the beginning of the year. In August, however, the company cut its expectations for operating profit growth.\"The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,\" CEO Lars Fruergaard Jorgensen said in a statement.Novo said operating profit between July and September rose 26% to 33.8 billion Danish crowns ($4.86 billion) compared with 33.6 billion forecast by analysts in a poll gathered by the company.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481635649"}